Navigation Links
BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
Date:11/10/2008

ing interest - 680

Shareholders' (deficiency) equity (28,512) 3,909

-------------------------------------------------------------------------

Total liabilities and shareholders'

(deficiency) equity $43,770 $78,431

-------------------------------------------------------------------------

-------------------------------------------------------------------------

(1) Condensed from the Company's unaudited consolidated financial

statements.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.

To Contact BELLUS Health

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1-877-680-4500 or visit the Web Site at http://www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and
'/>"/>

SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine news :

1. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
2. BELLUS Health provides update on activities
3. BELLUS Health announces closing of Innodia acquisition
4. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
5. BELLUS HEALTH reports results for first quarter of fiscal 2008
6. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
7. Healthcare Realty Trust Announces Third Quarter Results
8. World Publics See Government as Responsible for Ensuring Basic Healthcare, Food, and Education Needs
9. MAP Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
10. Major Mental Health Associations Join to Support Give an Hour
11. Wyeth to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 2Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 3Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 4Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 5Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 6Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 7Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 8Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 9GE Healthcare President 26 CEO Mark Vachon to Present at BioConference Live 10595 1GE Healthcare President 26 CEO Mark Vachon to Present at BioConference Live 10595 2Hepatitis B does not increase risk for pancreatic cancer 60451 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 3
Other Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8